参考文献/References:
[1]汪登斌.乳腺MRI应用现状和我国乳腺MRI应用中存在的问题[J].中华放射学杂志,2014,48(3):177-179.
[2]Sobin LH,Gospodarowicz MK,Wittekind C.TNM Classification of Malignant Tumours,7th edn[M].NEW YOＲK:Wiley-Black-well,2009.
[3]Fisher B,Brown A,Mamounas E,et al.Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer:findings from National Surgical Adjuvant Breast and Bowel Project B-18[J].Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology,1997,15(7):2483-2493.
[4]van der H age JA,van de V elde CJ,Julien JP,et al.Preoperative chemotherapy in primary operable breast cancer:results from the European Organization for research and treatment of cancer trial10902[J].JC lin O ncol,2001,19(22):4224-4237.
[5]Londero V,Bazzocchi M,D elFrate C,et al.Locally advanced breast cancer:comparison of m am m ography,sonography and M R im aging in evaluation of residual disease in women receiving neoadjuvant chemotherapy[J].Eur R adiol,2004,14(8):1371-1379.
[6]Kuhl C K,Mielcareck P,Klaschik S,et al.Dynamic breast MR imaging:are signal intensity time course data useful for differential diagnosis of enhancing lesions[J].Radiology,1999,211(1):101.
[7]王丽,仁友,蒋涛.乳腺疾病动态增强MRI半定量参数与微血管密度的相关性[J].中国医学影像技术,2007,23(3):388-392.
[8]Rosen EL,Blackwell K L,Baker JA,et al.Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy[J].A JR,2003,181(5):1275-1282.
[9]Londero V,Bazzocchi M,D el Frate C,et al.Locally advanced breast cancer:comparison of mammography,sonography and M R im aging in evaluation of residual disease in women receiving neoadjuvant chemotherapy[J].Eur Radiol,2004,14(8):1371-1379.
[10]Uematsu T,Kasami M,Yuen S.Neoadjuvant chemotherapy for breast cancer:correlation between the baseline MR imaging finding and responses to therapy[J].Eur Radiol,2010,20(10):2315-2322.
[11]Loo CE,Tertstra HJ,Rodenhuis S,et al.Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy:initial results[J].AJR Am J Roentgenol,2008,191(5):1331-1338.
[12]Huang B,Wong C S,Whitcher B,et al.Dynamic contrast-enhanced magnetic resonance imaging for characterising nasopharyngeal carcinoma:comparison of semiquantitative and quantitative parameters and correlation with tumour stage[J]. European Radiology,2013,23(6):1495-1502.
[13]杜永浩,牛刚,杨建.定量动态增强磁共振技术的影响因素分析[J].磁共振成像,2017,8(1):76-80.
[14]Tudorica A,Oh K Y,Chui S Y,et al.Early Prediction and Evaluation of Breast Cancer Response to Neoadjuvant Chemotherapy Using Quantitative DCE-MRI[J].Translational Oncology,2016,9(1):8．
[15]Ah-See M L,Makris A,Taylor N J,et al.Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research,2008,14(20):6580.
[16]Yu HJ,Chen JH,Mehta RS,et al.MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy[J].J Magn Reson Imaging,2007,26(3): 615-623．
[17]Wasser K,Klein S,Fink C,et al.Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution[J].European Radiology,2003,13(1):80-87.
[18]李瑞敏,顾雅佳,彭卫军,等.定量动态增强磁共振评估乳腺癌新辅助化疗疗效的应用研究[J].中国癌症杂志,2016,26(7):623-628.
[19]Wang Y,Huang W,Panicek D M,et al.Feasibility of using limited-population-based arterial input function for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced MRI data[J].Magnetic Resonance in Medicine,2008,59(5):1183-1189.
[20]Ogston K N,Miller I D,Payne S,et al.A new histological grading system to assess response of breast cancers to primary chemotherapy:prognostic significance and survival[J].Breast, 2003,12(5):320-327.
[21]尹波,刘莉,邹丽萍,等.乳腺癌新辅助化疗前后 ＤＣＥ－ＭＲＩ血流动力学与病理学对照[J].放射学实践,2011,26（3）：1062-1066.
相似文献/References:
[1]王文重,伊 扬,董晓昕,等.食管癌患者新辅助化疗前后生理指标变化及意义[J].医学信息,2022,35(09):116.[doi:10.3969/j.issn.1006-1959.2022.09.029]
WANG Wen-zhong,YI Yang,DONG Xiao-xin,et al.Changes and Significance of Physiological Indexes in Esophageal Cancer Patients Before and After Neoadjuvant Chemotherapy[J].Journal of Medical Information,2022,35(04):116.[doi:10.3969/j.issn.1006-1959.2022.09.029]
[2]张 虎,张 涛,徐 芳,等.MRI在乳腺癌诊治中的研究进展[J].医学信息,2022,35(10):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
ZHANG Hu,ZHANG Tao,XU Fang,et al.Research Progress of MRI in Diagnosis and Treatment of Breast Cancer[J].Journal of Medical Information,2022,35(04):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
[3]苏 志,吴 蔚,吴智钢,等.含洛铂方案新辅助化疗结合保肢手术治疗骨肉瘤的临床疗效观察[J].医学信息,2018,31(21):83.[doi:10.3969/j.issn.1006-1959.2018.21.022]
SU Zhi,WU Wei,WU Zhi-gang,et al.Clinical Efficacy of Neoadjuvant Chemotherapy with Lobaplatin Combined with Limb Salvage Surgery for OsteosarcomaC[J].Journal of Medical Information,2018,31(04):83.[doi:10.3969/j.issn.1006-1959.2018.21.022]
[4]王绥能,梁贤文,孙 光,等.伊立替康新辅助化疗在进展期胃癌的临床意义[J].医学信息,2018,31(24):164.[doi:10.3969/j.issn.1006-1959.2018.24.050]
WANG Sui-neng,LIANG Xian-wen,SUN Guang,et al.Clinical Significance of Irinotecan Neoadjuvant Chemotherapy in Advanced Gastric Carcinoma[J].Journal of Medical Information,2018,31(04):164.[doi:10.3969/j.issn.1006-1959.2018.24.050]
[5]黄 雨,楼浩男,涂 刚.Luminal B型乳腺癌TEC新辅助化疗疗效及影响因素分析[J].医学信息,2019,32(04):104.[doi:10.3969/j.issn.1006-1959.2019.04.033]
HUANG Yu,LOU Hao-nan,TU Gang.Analysis of the Efficacy and Influencing Factors of Neoadjuvant Chemotherapy for Luminal B Breast Cancer[J].Journal of Medical Information,2019,32(04):104.[doi:10.3969/j.issn.1006-1959.2019.04.033]
[6]李 博,李春晓.新辅助化疗在宫颈癌治疗中的应用[J].医学信息,2019,32(15):106.[doi:10.3969/j.issn.1006-1959.2019.15.034]
LI Bo,LI Chun-xiao.Application of Neoadjuvant Chemotherapy in the Treatment of Cervical Cancer[J].Journal of Medical Information,2019,32(04):106.[doi:10.3969/j.issn.1006-1959.2019.15.034]
[7]关利平,李建文.凝血相关指标与乳腺癌新辅助化疗疗效预测的相关性研究[J].医学信息,2022,35(16):159.[doi:10.3969/j.issn.1006-1959.2022.16.041]
GUAN Li-ping,LI Jian-wen.Study on Correlation Between Coagulation- related Indexes and Efficacy Prediction of Neoadjuvant Chemotherapy for Breast Cancer[J].Journal of Medical Information,2022,35(04):159.[doi:10.3969/j.issn.1006-1959.2022.16.041]
[8]付大鹏.多西他赛联合表柔比星新辅助化疗治疗乳腺癌的效果[J].医学信息,2020,33(05):149.[doi:10.3969/j.issn.1006-1959.2020.04.048]
FU Da-peng.Evaluation of Docetaxel Combined with Epirubicin Neoadjuvant Chemotherapy for Breast Cancer[J].Journal of Medical Information,2020,33(04):149.[doi:10.3969/j.issn.1006-1959.2020.04.048]
[9]王羽翎,孙佳威,周显礼.二维及三维实时剪切波弹性成像在乳腺肿块评估中的应用[J].医学信息,2020,33(11):42.[doi:10.3969/j.issn.1006-1959.2020.11.014]
WANG Yu-ling,SUN Jia-wei,ZHOU Xian-li.Application of 2D and 3D Real-time Shear Wave Elastography in Breast Mass Evaluation[J].Journal of Medical Information,2020,33(04):42.[doi:10.3969/j.issn.1006-1959.2020.11.014]
[10]周靖宇,单慧明,成官迅.基于支持向量机的全乳纹理分析预测乳腺癌新辅助化疗疗效的价值[J].医学信息,2022,35(19):60.[doi:10.3969/j.issn.1006-1959.2022.19.016]
ZHOU Jing-yu,SHAN Hui-ming,CHENG Guan-xun.Prediction of Neoadjuvant Chemotherapy Outcomes of Breast Cancer Based on Whole Breast Texture with Support Vector Machine[J].Journal of Medical Information,2022,35(04):60.[doi:10.3969/j.issn.1006-1959.2022.19.016]